# US 2026/0083728 A1 · Compounds for treating infections with parasitic protozoa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083728 A1
- Document ID: US20260083728A1
- Status: Published application
- Kind: A1
- Application number: 19/111,246
- Filed: 2023-09-18
- Published: 2026-03-26
- Earliest claimed: 2022-09-16
- Assignees: Ohio State Innovatiion Foundation; University of Kansas
- Applicants: Ohio State Innovatiion Foundation; University of Kansas
- Inventors: Karl WERBOVETZ; Pankaj SHARMA; Chris LA ROSA; Zhuo WANG; Yiru JIN; Mei FENG
- Web page: https://patentgrep.com/patent/US20260083728A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C07D 207/325: with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D 213/36: Radicals substituted by singly-bound nitrogen atoms (nitro radicals C07D213/26)
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/61: with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 295/192: from aromatic carboxylic acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular protozoa of the genera Leishmania or Trypanosoma.

## Claims

### Claim 1

A compound of Formula I
or a pharmaceutically acceptable salt or derivative thereof;
wherein:
R1 is selected from halo, cyano, azido, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C3-C6 cycloalkyl)-(C0-C3 alkyl)-, (3- to 8-membered monocyclic or bicyclic heterocycle)-(C0-C3 alkyl)-, (6- to 10-membered monocyclic or bicyclic aryl)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, RxO—(C0-C3 alkyl)-, RxS—(C0-C3 alkyl)-, (RxRyN)—(C0-C3 alkyl)-, RxO—C(O)—(C0-C3 alkyl)-, RxS—C(O)—(C0-C3 alkyl)-, (RxRyN) C(O)—(C0-C3 alkyl)-, RxO—S(O)2—(C0-C3 alkyl)-, (RxRyN) S(O)2—(C0-C3 alkyl)-, RzC(O)—O—(C0-C3 alkyl)-, RzC(O)—(RxN)—(C0-C3 alkyl)-, RzS(O)2—O—(C0-C3 alkyl)-, RzS(O)2—(RxN)—(C0-C3 alkyl)-, RzC(O)—(C0-C6 alkyl)-, RzS(O)—(C0-C3 alkyl)-, and RzS(O)2—(C0-C3 alkyl)-;
m is 0, 1, 2, 3, 4, or 5;
Rx and Ry are independently selected at each occurrence from hydrogen, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)-(C0-C3 alkyl)-, (4- to 6-membered heterocycle)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic aryl)-(C0-C3 alkyl)-, and (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, each of which may be optionally substituted with one or more Y groups as allowed by valency;
Rz is independently selected at each occurrence from hydrogen, halo, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)-(C0-C3 alkyl)-, (4- to 6-membered heterocycle)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic aryl)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, —ORx, —SRx, and —NRxRy, each of which may be optionally substituted with one or more Y groups as allowed by valency; and
Y is independently selected at each occurrence from alkyl, haloalkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycle, aldehyde, amino, carboxylic acid, ester, ether, halo, hydroxy, keto, nitro, cyano, azido, oxo, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, sulfonylamino, or thiol;
with the proviso that
cannot be 3,5-dimethylphenyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein
is selected from:

### Claim 3 (depends on 1)

A compound of claim 1 selected from
or a pharmaceutically acceptable salt or derivative thereof.

### Claim 4

A compound of Formula II
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is selected halo, cyano, azido, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C3-C6 cycloalkyl)-(C0-C3 alkyl)-, (3- to 8-membered monocyclic or bicyclic heterocycle)-(C0-C3 alkyl)-, (6- to 10-membered monocyclic or bicyclic aryl)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, RxO—(C0-C3 alkyl)-, RxS—(C0-C3 alkyl)-, (RxRyN)—(C0-C3 alkyl)-, RxO—C(O)—(C0-C3 alkyl)-, RxS—C(O)—(C0-C3 alkyl)-, (RxRyN) C(O)—(C0-C3 alkyl)-, RxO—S(O)2—(C0-C3 alkyl)-, (RxRyN)S(O)2—(C0-C3 alkyl)-, RzC(O)—O—(C0-C3 alkyl)-, RzC(O)—(RxN)—(C0-C3 alkyl)-, RzS(O)2—O—(C0-C3 alkyl)-, RzS(O)2—(RxN)—(C0-C3 alkyl)-, RzC(O)—(C0-C6 alkyl)-, RzS(O)—(C0-C3 alkyl)-, and RzS(O)2—(C0-C3 alkyl)-;
n is 0, 1, or 2;
p is 1, 2, 3, 4, or 5;
Ar1 is 6- to 10-membered monocyclic or bicyclic aryl or 5- to 10-membered monocyclic or bicyclic heteroaryl, wherein Ar1 is optionally substituted with one or more Z groups as allowed by valency;
Z is selected from hydrogen, halo, cyano, azido, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C3-C6 cycloalkyl)-(C0-C3 alkyl)-, (3- to 8-membered monocyclic or bicyclic heterocycle)-(C0-C3 alkyl)-, (6- to 10-membered monocyclic or bicyclic aryl)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, RxO—(C0-C3 alkyl)-, RxS—(C0-C3 alkyl)-, (RxRyN)—(C0-C3 alkyl)-, RxO—C(O)—(C0-C3 alkyl)-, RxS—C(O)—(C0-C3 alkyl)-, (RxRyN) C(O)—(C0-C3 alkyl)-, RxO—S(O)2—(C0-C3 alkyl)-, (RxRyN) S(O)2—(C0-C3 alkyl)-, RzC(O)—O—(C0-C3 alkyl)-, RzC(O)—(RxN)—(C0-C3 alkyl)-, RzS(O)2—O—(C0-C3 alkyl)-, RzS(O)2—(RzN)—(C0-C3 alkyl)-, RzC(O)—(C0-C6 alkyl)-, RzS(O)—(C0-C3 alkyl)-, and RzS(O)2—(C0-C3 alkyl)-;
Rx and Ry are independently selected at each occurrence from hydrogen, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)-(C0-C3 alkyl)-, (4- to 6-membered heterocycle)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic aryl)-(C0-C3 alkyl)-, and (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, each of which may be optionally substituted with one or more Y groups as allowed by valency;
Rz is independently selected at each occurrence from hydrogen, halo, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)-(C0-C3 alkyl)-, (4- to 6-membered heterocycle)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic aryl)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, —ORx, —SRx, and —NRxRy, each of which may be optionally substituted with one or more Y groups as allowed by valency; and
Y is independently selected at each occurrence from alkyl, haloalkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycle, aldehyde, amino, carboxylic acid, ester, ether, halo, hydroxy, keto, nitro, cyano, azido, oxo, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, sulfonylamino, or thiol.

### Claim 5 (depends on 4)

The compound of claim 4, wherein Ar1 is selected from:

### Claim 6 (depends on 4)

The compound of claim 4, wherein n is 0.

### Claim 7 (depends on 4)

The compound of claim 4, wherein n is 1.

### Claim 8 (depends on 4)

The compound of claim 4, wherein n is 2.

### Claim 9 (depends on 3)

The compound of claim 3, wherein
is selected from:

### Claim 10

A compound selected from:
or a pharmaceutically acceptable salt or derivative thereof.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 12 (depends on 1)

A method of treating or preventing an infection with a parasitic protozoa in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or derivative thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the parasitic protozoa expresses CYP51 and/or CYP5122A1.

### Claim 14 (depends on 12)

The method of claim 12, wherein the parasitic protozoa comprises a Leishmania parasite.

### Claim 15 (depends on 14)

The method of claim 14, wherein the Leishmania parasite comprises L. aethiopica, L. amazonensis, L. arabica, L. archibaldi, L. aristedesi, L. viannia, L. braziliensis, L. chagasi, L. colombiensis, L. deanei, L. donovani, L. enriettii, L. equatorensis, L. forattinii, L. garnhami, L. gerbili, L. guyanensis, L. herreri, L. hertigi, L. infantum, L. killicki, L. lainsoni, L. major, L. mexicana, L. naiffi, L. panamensis, L. peruviana, L. pifanoi, L. shawi, L. tarentolae, L. tropica, L. turanica, or L. venezuelensis.

### Claim 16 (depends on 12)

The method of claim 12, wherein the infection comprises cutaneous leishmaniasis, mucocutaneous leishmaniasis, or visceral leishmaniasis.

### Claim 17 (depends on 12)

The method of claim 12, wherein the parasitic protozoa comprises a Trypanosoma parasite.

### Claim 18 (depends on 17)

The method of claim 17, wherein the Trypanosoma parasite comprises T. ambystomae, T. avium, T. boissoni, T. brucei, T. cruzi, T. congolense, T. equinum, T. equiperdum, T. evansi, T. everetti, T. hosei, T. irwini, T. lewisi, T. melophagium, T. paddae, T. parroti, T. percae, T. rangeli, T. rotatorium, T. rugosae, T. sergenti, T. simiae, T. sinipercae, T. suis, T. theileri, T. triglae, or T. vivax.

### Claim 19 (depends on 12)

The method of claim 12, wherein the infection comprises African trypanosomiasis, Chagas disease, nagana, and surra.

### Claim 20 (depends on 12)

The method of claim 12, wherein the subject is a human, dog, cat, cow, horse, sheep, pig, bird, amphibian, or fish.
